The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Identity is verified. The requested target is human KITLG (approved name KIT ligand; UniProt P21583), also known as stem cell factor (SCF), mast-cell growth factor (MGF), c-KIT ligand, and Steel factor. The literature consistently describes it as a glycosylated, transmembrane SCF-family cytokine precursor whose cognate receptor is the class-III receptor tyrosine kinase KIT/CD117. This matches the supplied Homo sapiens record and does not represent a similarly named protein from another organism. The SCF-family and four-helix-cytokine-like annotations supplied by UniProt/InterPro are compatible with the literature; no conflicting identity was found. (sevilla2024therapeuticmodulationof pages 1-2)
KITLG is not an enzyme or transporter. Its primary function is to act as a spatially regulated signaling ligand. A noncovalent KITLG homodimer binds KIT on an adjacent or nearby target cell, promotes receptor dimerization and trans-autophosphorylation, and activates survival, proliferation, migration, differentiation, and activation programs. Alternative splicing and proteolytic shedding divide this function between a membrane-bound, largely juxtacrine signal and a diffusible soluble signal. (sevilla2024therapeuticmodulationof pages 1-2, zhao2020regulationofenergy pages 8-9, gavriilidis2020stemcellfactor pages 1-2)
| Feature/form | Molecular basis | Localization | Mechanistic consequence | Strongest evidence |
|---|---|---|---|---|
| Precursor identity and aliases (established) | Human KITLG, UniProt P21583; also called KIT ligand, stem cell factor (SCF), mast-cell growth factor (MGF) and Steel factor; glycosylated SCF-family cytokine precursor with a transmembrane segment | Secretory pathway and plasma membrane before processing | Produces cell-associated and soluble ligands for the receptor tyrosine kinase KIT/CD117; identity matches the supplied human UniProt record (sevilla2024therapeuticmodulationof pages 1-2) | Human-focused 2024 review identifies KITLG, aliases, genomic organization and protein class (sevilla2024therapeuticmodulationof pages 1-2) |
| SCF248 cleavable isoform (established) | Alternative splicing retains exon 6 and the protease-sensitive region containing the principal cleavage site; historically KL-1 | Synthesized as a type-I membrane protein, then substantially released into extracellular fluid | Enables both short-range membrane signaling and diffusible KIT stimulation; metalloprotease-dependent ectodomain shedding regulates the balance (sevilla2024therapeuticmodulationof pages 1-2, sevilla2024therapeuticmodulationof pages 17-18, gavriilidis2020stemcellfactor pages 1-2) | Differential processing studies and later shedding analyses; ADAM17 promotes stimulated shedding, while MMP-9 has also been implicated (sevilla2024therapeuticmodulationof pages 17-17, sevilla2024therapeuticmodulationof pages 17-18, gavriilidis2020stemcellfactor pages 1-2) |
| SCF220 membrane-retained isoform (established) | Alternative splicing excludes exon 6 and its major cleavage region; historically KL-2, although secondary shedding can occur | Predominantly plasma-membrane-associated, supporting juxtacrine signaling at cell–cell contacts | Generally elicits stronger or more sustained KIT activation than soluble ligand and supports adhesion, survival and spatially restricted niche signaling (sevilla2024therapeuticmodulationof pages 1-2, sevilla2024therapeuticmodulationof pages 13-13, zhao2020regulationofenergy pages 8-9) | Isoform-processing experiments plus mechanistic reviews comparing membrane and soluble SCF (sevilla2024therapeuticmodulationof pages 17-17, zhao2020regulationofenergy pages 8-9, gavriilidis2020stemcellfactor pages 1-2) |
| Soluble SCF/sKITLG (established; effects are context-dependent) | Proteolytically shed extracellular domain of cleavable KITLG; biologically active as a noncovalent homodimer | Extracellular space, interstitial fluid and culture medium; acts locally in paracrine or autocrine fashion | Activates KIT but usually produces more rapid and transient receptor phosphorylation than membrane SCF; can support proliferation, migration and survival, or promote inflammation depending on tissue (zhao2020regulationofenergy pages 8-9) | Biochemical/isoform evidence and disease models; SCF248 neutralization reduced inflammation and enhanced mucosal repair in mice, so this therapeutic interpretation is preclinical (zhao2020regulationofenergy pages 8-9, gavriilidis2020stemcellfactor pages 1-2) |
| KIT receptor activation (established) | Dimeric KITLG binds KIT/CD117, a class-III receptor tyrosine kinase, promoting receptor dimerization and trans-autophosphorylation | Cell surface of KIT-positive hematopoietic progenitors, mast cells, melanocytes and germ-cell lineages | Creates phosphotyrosine docking sites that initiate survival, proliferation, migration, differentiation and activation programs; KITLG is the only established KIT ligand (sevilla2024therapeuticmodulationof pages 1-2, zhao2020regulationofenergy pages 8-9) | Biochemical literature and authoritative mechanistic reviews consistently support ligand-induced KIT dimerization and phosphorylation (sevilla2024therapeuticmodulationof pages 1-2, zhao2020regulationofenergy pages 8-9) |
| Downstream signaling (established core; branch strength is context-dependent) | Activated KIT recruits signaling machinery feeding into PI3K–AKT, RAS–RAF–MEK–ERK/MAPK, PLCγ and JAK/STAT-related pathways | Cytoplasmic face of the plasma membrane and downstream cytosolic/nuclear compartments | Converts extracellular KITLG presentation into survival, mitogenic, motility and differentiation responses; membrane ligand commonly sustains MAPK signaling longer than soluble ligand (sevilla2024therapeuticmodulationof pages 1-2, zhao2020regulationofenergy pages 8-9) | Human-focused review lists PI3K, PLCγ, RAF/MEK, JAK2 and MAPK-related signaling; comparative review supports differential signal duration (sevilla2024therapeuticmodulationof pages 1-2, zhao2020regulationofenergy pages 8-9) |
| Hematopoietic stem/progenitor niche (established role; exact human source contributions remain under study) | KITLG is supplied by marrow stromal/perivascular populations and endothelial cells, cooperating with factors such as CXCL12 | Bone-marrow perivascular and stromal microenvironments | Supports HSPC retention, survival, maintenance, proliferation, differentiation and transplantation-associated engraftment (chen2023deconvolutionofhematopoietic pages 5-9, lee2024challengesandinnovations pages 2-3) | Human scRNA-seq detected KITLG in marrow stromal compartments: 46,740 cells from four healthy donors; functional source hierarchy is inferred rather than directly proven by this dataset (chen2023deconvolutionofhematopoietic pages 5-9) |
| Mast-cell niche (established) | Stromal-, epithelial- or other niche-derived KITLG engages KIT on mast-cell progenitors and mature mast cells | Connective tissues, skin and mucosa; membrane SCF acts at local cell contacts and soluble SCF can diffuse | Controls mast-cell development, survival, proliferation and activation; excessive KIT-pathway activity contributes to mast-cell accumulation, although KIT-mutant disease may become ligand-independent (sevilla2024therapeuticmodulationof pages 1-2, sevilla2024therapeuticmodulationof pages 5-6, sevilla2024therapeuticmodulationof pages 3-4) | Human mast-cell biology and translational antibody studies summarized in a 2024 domain review (sevilla2024therapeuticmodulationof pages 5-6, sevilla2024therapeuticmodulationof pages 13-13) |
| Melanocyte niche (established) | Keratinocyte- and endothelial-derived KITLG activates KIT on melanocyte-lineage cells; membrane presentation is especially important for local maintenance | Epidermis and hair-follicle pigmentary unit | Promotes melanocyte survival, migration, proliferation and melanogenesis; UVB and inflammatory mediators can alter KITLG expression, making pigmentation effects context-dependent (sevilla2024therapeuticmodulationof pages 5-6, sevilla2024therapeuticmodulationof pages 12-12) | Human genetics associates KITLG with pigmentation disorders, while cellular and animal studies support pathway causality (OpenTargets Search: -KITLG, sevilla2024therapeuticmodulationof pages 1-2, sevilla2024therapeuticmodulationof pages 5-6) |
| Germ-cell niche (established broadly; much mechanistic evidence is non-human) | Somatic gonadal support-cell KITLG signals to KIT-positive germ-cell precursors; correct surface sorting of membrane KITLG depends on its cytoplasmic domain | Testicular and ovarian germ-cell microenvironments | Supports germ-cell survival, migration and differentiation; disruption causes sterility phenotypes in experimental models (sevilla2024therapeuticmodulationof pages 1-2, sevilla2024therapeuticmodulationof pages 17-18) | Genetic and trafficking studies support the mechanism, but extrapolation of detailed niche regulation to humans should remain cautious (sevilla2024therapeuticmodulationof pages 1-2, sevilla2024therapeuticmodulationof pages 17-18) |
Table: Compact evidence map of human KITLG forms, processing, localization, KIT signaling and principal physiological niches. Established molecular facts are separated from context-dependent or predominantly preclinical findings.
The human KITLG locus is on chromosome 12 and comprises nine coding exons in the reviewed description. The encoded product enters the secretory pathway and is glycosylated before presentation as a type-I transmembrane cytokine. The supplied domain assignments—SCF/PF02404 and a four-helix-cytokine-like core—are therefore consistent with its established cytokine-ligand function. (sevilla2024therapeuticmodulationof pages 1-2)
SCF forms biologically active noncovalent homodimers. Dimerization enables productive engagement of two KIT receptor molecules. Reviews describe KITLG as the only established ligand for KIT. (zhao2020regulationofenergy pages 8-9, gavriilidis2020stemcellfactor pages 1-2)
Two major splice products differ by inclusion of exon 6:
Historical cell-biological experiments established differential processing of KL-1 and KL-2. Subsequent work implicated metalloproteases: ADAM17 promotes stimulated KITLG shedding, while MMP-9 has also been linked to release of the soluble ectodomain. The short cytoplasmic region contributes to secretory-pathway export and polarized/basolateral cell-surface sorting, showing that the membrane precursor is actively targeted rather than merely retained by default. (sevilla2024therapeuticmodulationof pages 17-17, sevilla2024therapeuticmodulationof pages 17-18, gavriilidis2020stemcellfactor pages 1-2)
KITLG functions in two principal extracellular configurations:
Thus, KITLG acts outside the ligand-producing cell, either while tethered to its surface or after release. Signal generation occurs at the plasma membrane of the KIT-expressing recipient cell.
Dimeric KITLG binds the extracellular region of KIT/CD117, bringing two receptor molecules together. This activates the intracellular tyrosine-kinase domains, causes trans-autophosphorylation, and creates docking sites for signaling proteins. The major downstream network includes PI3K–AKT, RAS–RAF–MEK–ERK/MAPK, PLCγ, and JAK/STAT-related signaling. The relative contribution of each branch depends on cell type and biological state. (sevilla2024therapeuticmodulationof pages 1-2, zhao2020regulationofenergy pages 8-9)
Ligand presentation changes signaling dynamics. Soluble SCF generally produces rapid, transient KIT phosphorylation, whereas membrane-associated ligand produces stronger or more prolonged receptor activation and sustained MAPK signaling. This difference provides a mechanistic explanation for why membrane KITLG is particularly effective in stable niches requiring continued survival, adhesion, or lineage maintenance. (zhao2020regulationofenergy pages 8-9, gavriilidis2020stemcellfactor pages 1-2)
The appropriate functional annotation is therefore: KIT receptor agonist and niche cytokine, not a broadly acting soluble growth factor alone. Splicing, trafficking, proteolysis, and the identity of the producing cell determine the signal's range and duration.
In bone marrow, KITLG is produced by stromal/perivascular and endothelial populations, with reviews also identifying pericytes, Nestin-positive stromal cells, and adipocyte-lineage cells as sources. Together with CXCL12 and other niche factors, it supports KIT-positive hematopoietic stem and progenitor-cell survival, retention, maintenance, proliferation, lineage differentiation, and post-transplant engraftment. The perivascular niche is generally associated with activation and differentiation, whereas endosteal contexts are more associated with quiescence; precise KITLG source contributions are state- and model-dependent. (chen2023deconvolutionofhematopoietic pages 5-9, lee2024challengesandinnovations pages 2-3, tomasoni2023elucidatingtheacute pages 16-21)
A 2023 human single-cell study analyzed 46,740 cells from four healthy marrow donors and detected KITLG in the bone-marrow stromal compartment, including perivascular MSC-like populations. This is strong evidence for cellular source localization in human marrow, but it measures RNA rather than secreted protein and does not by itself prove which stromal subtype supplies functionally indispensable KITLG. (chen2023deconvolutionofhematopoietic pages 5-9)
KITLG/KIT is a master survival and developmental pathway for mast-cell progenitors and mature mast cells. It regulates proliferation, tissue accumulation, activation, and degranulation. Membrane and soluble forms can have distinguishable effects: membrane KITLG is well suited to maintaining local cell populations, while soluble ligand can recruit or expand mast cells over a wider tissue range. In human LAD2 mast cells, an anti-soluble-KITLG antibody inhibited proliferation and degranulation, while related in-vivo studies reduced anaphylactic indicators; these are translationally suggestive but not yet evidence of routine human therapy. (sevilla2024therapeuticmodulationof pages 1-2, sevilla2024therapeuticmodulationof pages 5-6)
Pathological KIT activation must not be equated with KITLG dependence. In systemic mastocytosis, activating KIT mutations—especially D816V—can generate factor-independent growth, although KITLG may still modify cellular behavior. (sevilla2024therapeuticmodulationof pages 3-4)
Keratinocyte- and endothelial-derived KITLG acts on KIT-positive melanocyte-lineage cells to promote survival, migration, proliferation, differentiation, and melanin production. Membrane KITLG is especially important for local melanocyte maintenance in epidermal and hair-follicle niches. UVB and inflammatory mediators can increase KITLG production; UV-activated human dermal microvascular endothelial cells release soluble KITLG, providing a mechanistic connection between chronic sun exposure and hyperpigmentation. (sevilla2024therapeuticmodulationof pages 5-6, sevilla2024therapeuticmodulationof pages 12-12)
Human genetic evidence reinforces this function. Open Targets links KITLG to hair-color variation, familial progressive hyperpigmentation with or without hypopigmentation, Waardenburg syndrome 2F, and autosomal-dominant nonsyndromic hearing loss 69. The pigmentation and hearing phenotypes are biologically coherent because KIT signaling governs melanocyte-lineage development, including melanocytes needed for normal inner-ear physiology. (OpenTargets Search: -KITLG, sevilla2024therapeuticmodulationof pages 1-2)
Somatic support cells in gonadal niches provide KITLG to KIT-positive germ-cell precursors, promoting survival, migration, proliferation, and differentiation. Correct delivery of membrane KITLG to the cell surface is important: experimental disruption of its cytoplasmic sorting information affects spermatogenesis and hematopoiesis. Much of the detailed causal evidence derives from non-human genetic models, so the broad pathway is well established, while exact source-cell hierarchies in adult human gonads remain less certain. (sevilla2024therapeuticmodulationof pages 1-2, sevilla2024therapeuticmodulationof pages 17-18)
Recent work has shifted from treating SCF simply as a culture supplement toward resolving its native spatial context. The 2023 human marrow single-cell dataset identified KITLG-expressing stromal populations and resolved five HSC/MPP states; one quiescent LT-HSC-like cluster represented approximately 23.85 ± 1.18% of the analyzed HSC pool. These data connect KITLG source identity to heterogeneous recipient states, although functional dependence remains inferred rather than experimentally deleted in humans. (chen2023deconvolutionofhematopoietic pages 5-9)
A July 2024 review emphasized that conventional murine xenografts incompletely reproduce human cytokine and niche biology and highlighted marrow organoids and marrow-on-chip systems as emerging alternatives. This is an important expert assessment: KITLG function is highly presentation-dependent, so models reproducing membrane display, extracellular matrix, vascular organization, and cell proximity should be more informative than soluble-SCF-only cultures. (lee2024challengesandinnovations pages 2-3)
A 2024 fetal-liver-like organoid preprint used recombinant human SCF at 100 ng/mL from differentiation day 6, together with FGF2, VEGF, IL-6, IL-11, IGF1, and EPO, to support pluripotent-stem-cell-derived hematopoiesis. The model was subsequently tested in NSG mice. Because SCF was one component of a multicytokine cocktail and the work was a preprint, it demonstrates current implementation rather than isolated KITLG causality or clinical efficacy. (rezvani2024fetalliverlikeorganoids pages 26-29)
A May 2024 expert review concluded that KITLG/KIT is a master regulatory system shared by melanocytes and mast cells. It identified potential opportunities in vitiligo, hair greying, melasma, urticaria, mastocytosis, and melanoma, while stressing that pathway blockade may deplete beneficial melanocyte or mast-cell populations and pathway stimulation may cause hyperpigmentation or mast-cell activation. This bidirectional toxicity is a central translational constraint. (sevilla2024therapeuticmodulationof pages 17-17, sevilla2024therapeuticmodulationof pages 12-12)
Candidate interventions include reducing KITLG expression or shedding, neutralizing soluble KITLG, blocking KIT with antibodies, and inhibiting KIT kinase activity. Imatinib and the anti-KIT antibody CDX-0159 illustrate receptor-directed approaches; neither is a KITLG-specific approved treatment, and effects on KIT-mutant disease vary with mutation and biological context. (sevilla2024therapeuticmodulationof pages 12-12, sevilla2024therapeuticmodulationof pages 3-4)
Recombinant human SCF is routinely used in ex-vivo HSPC maintenance, expansion, differentiation, colony assays, and cell-manufacturing protocols, usually in combinations that include FLT3 ligand, thrombopoietin, and lineage-specific cytokines. It is also incorporated into pluripotent-stem-cell hematopoietic differentiation systems and organoid protocols. The key limitation is that soluble recombinant SCF does not fully reproduce membrane-bound, polarized KITLG in a native niche. (lee2024challengesandinnovations pages 2-3, rezvani2024fetalliverlikeorganoids pages 26-29)
Humanized mouse strains expressing human SCF are used to improve development or persistence of human myeloid populations. These models are valuable in immuno-oncology and inflammatory research but can create nonphysiological constitutive cytokine exposure and should not be interpreted as direct models of normal human KITLG regulation.
KITLG itself is better established as a culture reagent and mechanistic target than as a routinely administered drug. Earlier hematopoietic-development programs explored recombinant SCF because of its potent synergy with other colony-stimulating factors, but broad mast-cell activation and other on-target effects constrain systemic administration. Contemporary translation has consequently emphasized localized delivery, engineered niches, isoform-selective neutralization, or receptor-directed therapy rather than chronic systemic SCF exposure. The reviewed 2023–2024 evidence does not establish an approved KITLG-specific therapeutic indication. (sevilla2024therapeuticmodulationof pages 13-13, sevilla2024therapeuticmodulationof pages 12-12)
KITLG variation or dysregulation is associated with pigmentation phenotypes, hearing loss, testicular cancer susceptibility, inflammatory and fibrotic responses, and altered tumor microenvironments. Open Targets reports associations with hair color, testicular cancer, familial progressive pigmentary disease, nonsyndromic hearing loss 69, and Waardenburg syndrome 2F. These associations combine genetic and literature evidence and do not imply that all conditions would respond to KITLG inhibition. (OpenTargets Search: -KITLG)
Context is decisive. Elevated soluble KITLG can be pro-inflammatory in some tissues, while membrane KITLG can be required for normal niche maintenance. Conversely, malignant cells may exploit autocrine or stromal SCF/KIT signaling, but cancers driven by constitutively active KIT can become partly ligand-independent. Therapeutic proposals must therefore distinguish: (i) ligand-dependent versus receptor-mutant disease; (ii) membrane versus soluble KITLG; and (iii) local versus systemic intervention. (sevilla2024therapeuticmodulationof pages 5-6, sevilla2024therapeuticmodulationof pages 3-4, gavriilidis2020stemcellfactor pages 1-2)
The strongest functional annotation is supported by convergent biochemical, cell-biological, genetic, and human transcriptomic evidence. KITLG is a dimeric extracellular cytokine ligand whose membrane-tethered and soluble forms activate KIT with different spatial and temporal properties. Its most precisely established physiological role is to provide a niche signal for KIT-positive hematopoietic progenitors, mast cells, melanocytes, and germ-cell lineages. (sevilla2024therapeuticmodulationof pages 1-2, chen2023deconvolutionofhematopoietic pages 5-9, zhao2020regulationofenergy pages 8-9)
The 2023–2024 literature adds higher-resolution human niche mapping and more physiological organoid/on-chip strategies, but it does not overturn the core model. Important unresolved questions include the quantitative contribution of each human stromal source, isoform-specific protein abundance in vivo, and whether selective targeting of soluble SCF can suppress disease while preserving essential membrane-SCF functions. Current expert opinion favors tissue- and isoform-selective modulation over indiscriminate systemic blockade or stimulation. (sevilla2024therapeuticmodulationof pages 12-12, chen2023deconvolutionofhematopoietic pages 5-9, lee2024challengesandinnovations pages 2-3)
References
(sevilla2024therapeuticmodulationof pages 1-2): Alec Sevilla and James M. Grichnik. Therapeutic modulation of kit ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology, May 2024. URL: https://doi.org/10.1111/exd.15091, doi:10.1111/exd.15091. This article has 5 citations and is from a domain leading peer-reviewed journal.
(zhao2020regulationofenergy pages 8-9): Meng Zhao, Yunshin Jung, Zewen Jiang, and Katrin J. Svensson. Regulation of energy metabolism by receptor tyrosine kinase ligands. Frontiers in Physiology, Apr 2020. URL: https://doi.org/10.3389/fphys.2020.00354, doi:10.3389/fphys.2020.00354. This article has 67 citations.
(gavriilidis2020stemcellfactor pages 1-2): George I. Gavriilidis, Stavroula Ntoufa, Nikos Papakonstantinou, Konstantia Kotta, Triantafyllia Koletsa, Elisavet Chartomatsidou, Theodoros Moysiadis, Niki Stavroyianni, Achilles Anagnostopoulos, Eleni Papadaki, Asterios S. Tsiftsoglou, and Kostas Stamatopoulos. Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia. Haematologica, 106:692-700, Mar 2020. URL: https://doi.org/10.3324/haematol.2019.236513, doi:10.3324/haematol.2019.236513. This article has 11 citations.
(sevilla2024therapeuticmodulationof pages 17-18): Alec Sevilla and James M. Grichnik. Therapeutic modulation of kit ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology, May 2024. URL: https://doi.org/10.1111/exd.15091, doi:10.1111/exd.15091. This article has 5 citations and is from a domain leading peer-reviewed journal.
(sevilla2024therapeuticmodulationof pages 17-17): Alec Sevilla and James M. Grichnik. Therapeutic modulation of kit ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology, May 2024. URL: https://doi.org/10.1111/exd.15091, doi:10.1111/exd.15091. This article has 5 citations and is from a domain leading peer-reviewed journal.
(sevilla2024therapeuticmodulationof pages 13-13): Alec Sevilla and James M. Grichnik. Therapeutic modulation of kit ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology, May 2024. URL: https://doi.org/10.1111/exd.15091, doi:10.1111/exd.15091. This article has 5 citations and is from a domain leading peer-reviewed journal.
(chen2023deconvolutionofhematopoietic pages 5-9): Lanpeng Chen, Eline Pronk, Claire van Dijk, Yujie Bian, Jacqueline Feyen, Tim van Tienhoven, Meltem Yildirim, Paola Pisterzi, Madelon de Jong, Alejandro Bastidas, Remco Hoogenboezem, Chiel Wevers, Eric Bindels, Bob Löwenberg, Tom Cupedo, Mathijs A. Sanders, and Marc H.G.P. Raaijmakers. Deconvolution of hematopoietic stem/progenitor cell signaling predicts inflammatory niche remodeling to be a determinant of tissue failure and outcome in human aml. bioRxiv, May 2023. URL: https://doi.org/10.1101/2023.05.05.539525, doi:10.1101/2023.05.05.539525. This article has 0 citations.
(lee2024challengesandinnovations pages 2-3): Byung-Chul Lee. Challenges and innovations in hematopoietic stem cell transplantation: exploring bone marrow niches and new model systems. Jul 2024. URL: https://doi.org/10.5483/bmbrep.2024-0074, doi:10.5483/bmbrep.2024-0074. This article has 6 citations and is from a peer-reviewed journal.
(sevilla2024therapeuticmodulationof pages 5-6): Alec Sevilla and James M. Grichnik. Therapeutic modulation of kit ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology, May 2024. URL: https://doi.org/10.1111/exd.15091, doi:10.1111/exd.15091. This article has 5 citations and is from a domain leading peer-reviewed journal.
(sevilla2024therapeuticmodulationof pages 3-4): Alec Sevilla and James M. Grichnik. Therapeutic modulation of kit ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology, May 2024. URL: https://doi.org/10.1111/exd.15091, doi:10.1111/exd.15091. This article has 5 citations and is from a domain leading peer-reviewed journal.
(sevilla2024therapeuticmodulationof pages 12-12): Alec Sevilla and James M. Grichnik. Therapeutic modulation of kit ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology, May 2024. URL: https://doi.org/10.1111/exd.15091, doi:10.1111/exd.15091. This article has 5 citations and is from a domain leading peer-reviewed journal.
(OpenTargets Search: -KITLG): Open Targets Query (-KITLG, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(tomasoni2023elucidatingtheacute pages 16-21): C Tomasoni. Elucidating the acute myeloid leukemia-mediated reshaping of bone marrow stromal niche. Unknown journal, 2023.
(rezvani2024fetalliverlikeorganoids pages 26-29): Milad Rezvani, Kyle Lewis, Susanna Quach, Kentaro Iwasawa, Julian Weihs, Hasan Al Reza, Yuqi Cai, Masaki Kimura, RanRan Zhang, Yuka Milton, Praneet Chaturvedi, Konrad Thorner, Ramesh C. Nayak, Jorge Munera, Phillip Kramer, Brian R. Davis, Appakalai N. Balamurugan, Yeni Ait Ahmed, Marcel Finke, Rose Yinghan Behncke, Adrien Guillot, René Hägerling, Julia K. Polansky, Philip Bufler, Jose A Cancelas, James M. Wells, Momoko Yoshimoto, and Takanori Takebe. Fetal liver-like organoids recapitulate blood-liver niche development and multipotent hematopoiesis from human pluripotent stem cells. bioRxiv, Oct 2024. URL: https://doi.org/10.1101/2024.10.11.617794, doi:10.1101/2024.10.11.617794. This article has 7 citations.